DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Multi-center Trial to Determine if Curosurf� Reduces the Duration of Mechanical Ventilation in Infants 24+0 to 29+6 Weeks Gestational Age

Information source: Ottawa Hospital Research Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Respiratory Distress Syndrome

Intervention: Curosurf-Group1 (Drug); BLES-group 2 (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Ottawa Hospital Research Institute

Official(s) and/or principal investigator(s):
Brigitte Lemyre, MD, Principal Investigator, Affiliation: OHRI

Overall contact:
Brigitte Lemyre, MD, Phone: 6137378899, Ext: 71882, Email: blemyre@ottawahospital.on.ca

Summary

The purpose of this study is to see if a medication called Curosurf can reduce the length of time that small premature babies with Respiratory Distress Syndrome (immature lungs) or RDS, stay on the ventilator, as compared to the standard medication called BLES. Curosurf is a medication that is already used in other countries around the world but not yet in Canada. Babies born under 30 weeks of gestation frequently need respiratory support after birth, including being placed on a breathing machine or respirator. The most common reason is Respiratory Distress Syndrome (RDS) whereby immature lungs don't produce enough surfactant, a soapy like substance that helps the air sacs open and close. Our current standard treatment is a surfactant called BLES. Curosurf contains more active ingredient per volume therefore the amount is smaller. The investigators hypothesize that babies who receive Curosurf will be able to be removed from the ventilator sooner. Babies in this study will have a 50/50 chance of receiving either Curosurf or BLES and the investigators will monitor their progress during their Neonatal Intensive Care Unit admission. The study is taking place in Canada. The goal is to enroll 88 babies. There are no extra tests (blood tests or X-Rays) or return visits to the hospital for the purposes of this study.

Clinical Details

Official title: A Randomized, Controlled, Partially Double-blinded, Phase 3, Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Infants 24+0 to 29+6 Weeks Gestational Age

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The primary objective of the study is to compare between the two groups, the number of subjects alive and extubated at 48 hours post surfactant administration. Extubation

Secondary outcome:

To compare the duration of respiratory support, extubation failure rates, need for additional surfactant doses, adverse events (during and following administration), survival and pulmonary morbidities during hospital admission between the two groups.

Curosurf-01

Curosurf-01

Curosurf-01

Curosurf-01

Curosurf-01

Curosurf-01

Eligibility

Minimum age: 24 Weeks. Maximum age: 29 Weeks. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Infants born between 24+0 and 29+6 weeks gestational age, admitted to the study centers 2. Infants with RDS requiring intubation and surfactant therapy within 48 hours after birth Exclusion Criteria: 1. Any infant more than 48 hours of age 2. Any infant with a pulmonary hemorrhage 3. Any infant with life-threatening congenital anomaly or one that is considered non-viable 4. Any infant on a high frequency ventilator 5. Any infant known to require early intubation and ventilation for surgical treatment of a congenital anomaly 6. Any infant with anomalies of the upper or lower airway or mandible precluding use of nCPAP 7. Any infant born after prolonged premature rupture of membranes (<22 weeks GA or >14 days prior to delivery) 8. A parent/LAR who is incapable of, or unwilling, to give consent 9. Participation in another clinical trial of any placebo, drug, biological, or device conducted under the provisions of a protocol 10. Any other reason as deemed significant by the Investigator

Locations and Contacts

Brigitte Lemyre, MD, Phone: 6137378899, Ext: 71882, Email: blemyre@ottawahospital.on.ca

The Ottawa Hospital, Ottawa, Ontario K1H8L6, Canada; Recruiting
Lynne Cullen, RN, Phone: 6137377600, Ext: 3782, Email: lcullen@cheo.on.ca
Samantha Somers, BA, Phone: 6137377600, Ext: 2794, Email: ssomers@cheo.on.ca
Brigitte Lemyre, MD, Principal Investigator
Additional Information

Product information

Starting date: March 2013
Last updated: September 27, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017